These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35831917)

  • 21. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
    Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.
    Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S
    J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib.
    Till KJ; Abdullah M; Alnassfan T; Janet GZ; Marks T; Coma S; Weaver DT; Pachter JA; Pettitt AR; Slupsky JR
    Sci Rep; 2023 Mar; 13(1):3793. PubMed ID: 36882482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
    Liu X; Wang A; Liang X; Liu J; Zou F; Chen C; Zhao Z; Deng Y; Wu H; Qi Z; Wang B; Wang L; Liu F; Xu Y; Wang W; Fernandes SM; Stone RM; Galinsky IA; Brown JR; Loh T; Griffin JD; Zhang S; Weisberg EL; Zhang X; Liu J; Liu Q
    Oncotarget; 2016 Aug; 7(33):53515-53525. PubMed ID: 27447747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
    Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
    Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.
    Cai Y; Yu J; Ren P; He J; Wu Z; Xiao K; Jia H; Wang J; Sai Y; Dai G; Li X; Su W; Ngo K; Castro G; Acton PD; Fung-Leung WP; Edwards JP; Venable J; Rao TS
    Pharmacol Res Perspect; 2020 Feb; 8(1):e00559. PubMed ID: 31956418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.
    Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y
    Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.
    Henley ZA; Amour A; Barton N; Bantscheff M; Bergamini G; Bertrand SM; Convery M; Down K; Dümpelfeld B; Edwards CD; Grandi P; Gore PM; Keeling S; Livia S; Mallett D; Maxwell A; Price M; Rau C; Reinhard FBM; Rowedder J; Rowland P; Taylor JA; Thomas DA; Hessel EM; Hamblin JN
    J Med Chem; 2020 Jan; 63(2):638-655. PubMed ID: 31855425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations.
    Liang JW; Wang S; Wang MY; Li SL; Li WQ; Meng FH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3Kδ inhibitors.
    Hamajima T; Takahashi F; Kato K; Mukoyoshi K; Yoshihara K; Yamaki S; Sugano Y; Moritomo A; Yamagami K; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 May; 26(9):2410-2419. PubMed ID: 29631787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
    Ameriks MK; Venable JD
    Curr Top Med Chem; 2009; 9(8):738-53. PubMed ID: 19689378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
    Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
    J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.
    Erra M; Taltavull J; Gréco A; Bernal FJ; Caturla JF; Gràcia J; Domínguez M; Sabaté M; Paris S; Soria S; Hernández B; Armengol C; Cabedo J; Bravo M; Calama E; Miralpeix M; Lehner MD
    ACS Med Chem Lett; 2017 Jan; 8(1):118-123. PubMed ID: 28105286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
    Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
    Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.
    Down K; Amour A; Anderson NA; Barton N; Campos S; Cannons EP; Clissold C; Convery MA; Coward JJ; Doyle K; Duempelfeld B; Edwards CD; Goldsmith MD; Krause J; Mallett DN; McGonagle GA; Patel VK; Rowedder J; Rowland P; Sharpe A; Sriskantharajah S; Thomas DA; Thomson DW; Uddin S; Hamblin JN; Hessel EM
    J Med Chem; 2021 Sep; 64(18):13780-13792. PubMed ID: 34510892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of AS2541019, a novel selective PI3Kδ inhibitor, on antibody production and hamster to rat xenotransplantation.
    Marui T; Fukahori H; Kawashima T; Ito M; Akamatsu M; Kaneko Y; Takahashi F; Imada S; Morokata T
    Eur J Pharmacol; 2018 May; 826():179-186. PubMed ID: 29518396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.